The pharmaceutical firm co-led a series A equity and crossover financing round for the life sciences tool provider that will fund Chinese expansion.
Singapore-based life sciences tool provider Esco Lifesciences completed $200m in series A and crossover funding yesterday, with pharmaceutical firm Novo co-leading the financing.
Venture capital firm Vivo Capital co-led the round, which also featured sovereign wealth fund China Investment Corporation and the Singaporean state-owned EDBI.
Esco manufactures tools for use in diagnostic sample preparation, cultivation, storage and analysis, in addition to larger-scale products like mobile diagnostic laboratories, covid-19 swab booths and airborne infection isolation rooms.
The funding will support the…
